CUL1

Cullin-1 · Q13616 · CUL1 on Sugi Atlas →

0 patent compounds predicted against CUL1, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CUL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients PHASE4NOT_YET_RECRUITING
Can We Achieve 'high-quality' Weight Loss Through Supplementation and Exercise? the TRIM MUSCLE Study PHASE3COMPLETED
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers PHASE2NOT_YET_RECRUITING
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Olaparib in Patients With HRD Malignant Mesothelioma PHASE2RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes PHASE2UNKNOWN
The Effect of Roxadustat on Renal Oxygenation in Diabetes Nephropathy PHASE2NOT_YET_RECRUITING
Phase I Study of a Monoclonal Antibody for Treatment of Advanced Adenocarcinomas PHASE1COMPLETED
GO-203-2C + Bortezomib For Relapsed Or Refractory MM PHASE1WITHDRAWN
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease EARLY_PHASE1RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors nanNOT_YET_RECRUITING
ADAPT: Efficacy of a Dietary Supplement During and After Exercise nanCOMPLETED
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) nanUNKNOWN
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin nanUNKNOWN
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome nanRECRUITING
Drivers of Hypoxia-induced Angiogenesis in Tumor Development nanUNKNOWN
Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease? nanUNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis nanUNKNOWN
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients nanRECRUITING
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 nanRECRUITING
Mitochondrial Activity and Myosteatosis in the Cachexia of Cancers of the Upper Aerodigestive Tract nanUNKNOWN
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study nanRECRUITING
Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants nanRECRUITING
Characterization of Angelman Syndrome nanCOMPLETED
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders nanRECRUITING
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 nanNOT_YET_RECRUITING
HYPOCHOL : A Genetically-based Strategy to Identify New Targets in Cholesterol Metabolism nanACTIVE_NOT_RECRUITING
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CUL1 binder may also engage these)

ProteinNameSimilarity
Q5R4G6 1.000 Q5R4G6 →
Q9WTX6 1.000 Q9WTX6 →
Q5RBI3 0.963 Q5RBI3 →
Q0WQF4 0.963 Q0WQF4 →
Q9JJ31 0.962 Q9JJ31 →
Q29425 0.961 Q29425 →
Q2KJ25 0.961 Q2KJ25 →
PSMD12 26S proteasome non-ATPase regulatory subunit 12 0.959 landscape →
Q8R1U1 0.959 Q8R1U1 →
BZW2 eIF5-mimic protein 1 0.958 landscape →
Q9D5V5 0.958 Q9D5V5 →
Q5RB36 0.958 Q5RB36 →
Q5R882 0.958 Q5R882 →
Q7QG73 0.957 Q7QG73 →
Q91XD6 0.957 Q91XD6 →
EIF3L Eukaryotic translation initiation factor 3 subunit L 0.957 landscape →
Q5E993 0.957 Q5E993 →
Q3ZCK1 0.957 Q3ZCK1 →
Q8CCB4 0.956 Q8CCB4 →
Q9D8W5 0.956 Q9D8W5 →
COG6 Conserved oligomeric Golgi complex subunit 6 0.956 landscape →
Q9V345 0.956 Q9V345 →
Q68FP9 0.956 Q68FP9 →
Q3MHG0 0.956 Q3MHG0 →
P0C0A2 0.955 P0C0A2 →
Q66HV4 0.955 Q66HV4 →
A5PK00 0.955 A5PK00 →
Q8R3I3 0.955 Q8R3I3 →
Q5R7R6 0.955 Q5R7R6 →
Q7T2A5 0.955 Q7T2A5 →